Article
Survival improvement of patients with FLT3 mutated acute myeloid leukemia: results from a prospective 9 years cohort.
Blood cancer journal - 5 May 2023
Oñate Guadalupe, Pratcorona Marta, Garrido Ana, Artigas-Baleri Alicia, Bataller Alex, Tormo Mar, Arnan Montserrat, Vives Susana, Coll Rosa, Salamero Olga, Vall-Llovera Ferran, Sampol Antònia, Garcia Antoni, Cervera Marta, Avila Sara Garcia, Bargay Joan, Ortín Xavier, Nomdedéu Josep F, Esteve Jordi, Sierra Jorge
Abstract excerpt
Midostaurin added to intensive chemotherapy is the standard of care for acute myeloid leukemia (AML) with FLT3 mutations (FLT3mut). We analyzed the impact of midostaurin in 227 FLT3mut-AML patients included in the AML-12 prospective trial for fit patients ≤70 years (#NCT04687098). Patients were divided into an early (2012-2015) and late (2016-2020) cohorts. They were uniformly treated except for the addition of...
Topics
- Humans
- Nucleophosmin
- Prospective Studies
- Mutation
- Leukemia, Myeloid, Acute
- Prognosis
- fms-Like Tyrosine Kinase 3